中国药业2024，Vol.33Issue(12)：1-6,6.DOI:10.3969/j.issn.1006-4931.2024.12.001
PD-1/PD-L1小分子抑制剂研究进展
Research Progress on Small Molecule Inhibitors of PD-1/PD-L1
摘要
Abstract
Objective To provide a reference for the research and development(R&D)of novel small molecule inhibitors of programmed death-1(PD-1)/programmed death-ligand 1(PD-L1).Methods The studies related to small molecule inhibitors of PD-1/PD-L1 in the PubMed,Embase,Web of Science,ClinicalTrails.gov,CNKI and WanFang databases from 2010 to 2023 were searched to summarize and analyze the R&D status of these inhibitors.Results and Conclusion There are 20 small molecule inhibitors of PD-1/PD-L1 with the potential to develop into drugs,including CA-170(oral small molecule inhibitor),INCB086550(specific PD-L1 inhibitor),DPPA-1(peptide antagonists specifically inhibiting the interaction of PD-1/PD-L1)and so on.The first two are already in clinical trial stage.The small molecule inhibitors of PD-1/PD-L1 can specifically inhibit immune checkpoints,and they can be taken orally,have good stability and high membrane permeability,but their therapeutic effects still need to be verified through clinical trials.关键词
程序性死亡受体-1/程序性死亡配体-1/小分子抑制剂/免疫检查点/抗肿瘤药物/靶向治疗Key words
programmed death-1/programmed death-ligand 1/small molecule inhibitor/immune checkpoint/antitumor drug/targeted therapy分类
医药卫生引用本文复制引用
张大猛,陈美宇,徐静,杜沛龙,朱馨婷,韩冷,郭澄,杨全军..PD-1/PD-L1小分子抑制剂研究进展[J].中国药业,2024,33(12):1-6,6.基金项目
国家自然科学基金[82272925] （）
上海市浦江人才计划项目[21PJ1411900] （）
上海市第六人民医院院级管理类科研基金[沪六院内科字[2023]第1号] （）
上海市第六人民医院医疗服务能级提升工程医政管理优化项目[20220201]. （）
